Analyst Conference Summaries |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Mylan, Inc.
|
Analyst Call Notes by William P. Meyers |
|||
2019 | |||
Mylan Q1 2019 |
Mylan Q2 2019 |
||
May 7, 2019 | July 29, 2019 | ||
2018 |
|||
Mylan Q4 2018 |
|||
May 9, 2018 |
August 8, 2018 |
Nov. 5, 2018 |
Feb. 26, 2019 |
2017 |
|||
May 10, 2017 |
August 9, 2017 |
Nov. 6, 2017 |
Feb. 28, 2018 |
2016 |
|||
05/03/2016 |
08/09/2016 |
11/09/2016 |
03/01/2017 |
2015 |
|||
05/05/2015 |
08/06/2015 |
10/30/2015 |
02/10/2016 |
2014 |
|||
05/01/2014 |
08/07/2014 |
10/30/2014 |
03/02/2015 |
2013 |
|||
08/01/2013 |
10/31/2013 |
02/27/2014 |
Mylan is Deeply Undervalued [August 27, 2014]
Mylan Pursues Global Generics Dominance Strategy [September 6, 2013]
Mylan (MYL) is a manufacturer of generic drugs and therapies.
Mylan web site
Mylan investor relations page
I took an initial position in Mylan on March 20, 2014
More Analyst Conference Pages:
AGEN |
AGIO |
ALNY |
ALXN |
AMAT |
AMGN |
BIIB |
CLDX |
CELG |
EPZM |
GILD |
GLYC |
INCY |
INO |
ISRG |
MCHP |
PLX |
REGN |
SGEN |
TTPH |
VBLT |
VSTM |
XLNX |
XLRN |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. These are my personal notes, not financial advice, and may be the basis of my Seeking Alpha articles.
Copyright 2019 William P. Meyers